New York State Common Retirement Fund Sells 3,399,839 Shares of Halozyme Therapeutics, Inc. $HALO

New York State Common Retirement Fund lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 98.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 63,127 shares of the biopharmaceutical company’s stock after selling 3,399,839 shares during the period. New York State Common Retirement Fund’s holdings in Halozyme Therapeutics were worth $4,630,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Root Financial Partners LLC purchased a new stake in shares of Halozyme Therapeutics in the third quarter valued at $25,000. Richardson Financial Services Inc. boosted its stake in shares of Halozyme Therapeutics by 87.6% during the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares during the period. Newbridge Financial Services Group Inc. bought a new position in Halozyme Therapeutics during the 2nd quarter valued at about $32,000. Employees Retirement System of Texas bought a new position in Halozyme Therapeutics during the 2nd quarter valued at about $34,000. Finally, First Horizon Corp purchased a new stake in Halozyme Therapeutics in the 3rd quarter worth about $56,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Citizens Jmp boosted their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Finally, The Goldman Sachs Group reissued a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $78.80.

Halozyme Therapeutics Trading Up 3.6%

Shares of NASDAQ HALO opened at $81.23 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $81.36. The firm has a market cap of $9.55 billion, a PE ratio of 17.10, a price-to-earnings-growth ratio of 0.33 and a beta of 0.97. The business has a fifty day simple moving average of $69.43 and a two-hundred day simple moving average of $69.08. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59.

Insider Activity

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $68.48, for a total transaction of $136,960.00. Following the transaction, the director owned 42,952 shares of the company’s stock, valued at approximately $2,941,352.96. This trade represents a 4.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the completion of the sale, the chief executive officer owned 708,719 shares of the company’s stock, valued at approximately $53,947,690.28. This represents a 2.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 71,398 shares of company stock worth $5,170,152. 2.40% of the stock is owned by company insiders.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Company raised 2025 and 2026 revenue guidance, prompting fresh valuation attention and supporting higher expectations for revenue growth going forward. This is a primary driver of the intraday uptick. A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance
• Positive Sentiment: Analysts have been revising near-term earnings and EPS forecasts upward (including a raised Q1 EPS estimate), which supports investor sentiment and higher price targets. Upward analyst revisions tend to lift momentum in the shares. Research Analysts Offer Predictions for HALO FY2025 Earnings
• Positive Sentiment: Recent quarterly results (Nov. 3) showed an EPS and revenue beat and strong margins/ROE, reinforcing the thesis that ENHANZE-driven royalties and commercial growth can sustain higher profitability. That fundamental strength underpins current multiple expansion. MarketBeat Halozyme summary and earnings recap
• Neutral Sentiment: Longer-term thematic coverage notes medtech companies seeing multi‑decade growth opportunities; if Halozyme is included in that narrative it could support longer-duration investor interest but is more thematic than immediately catalytic. This medical technology leader sees growth into the 2040s
• Neutral Sentiment: Institutional ownership remains very high (~98%) and analyst ratings are mixed (buys, holds, one sell). That concentration can amplify moves but also limits free float liquidity. MarketBeat institutional & analyst snapshot
• Negative Sentiment: CEO Helen Torley has sold multiple blocks of shares recently (10,000 shares on Feb 5 at ~$78.64; prior sales of 20,000 at ~$76.12 and other sales in 2025/2024). Insider selling can create short‑term pressure or raise governance questions for some investors. Insider Selling: Halozyme Therapeutics CEO Sells 10,000 Shares

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.